Tamoxifen, a selective-estrogen receptor modulator, is highly effective for breast cancer prevention among high-risk women1–3 and significantly reduces the risk of recurrence, second breast cancer, and mortality in the adjuvant setting among women diagnosed with estrogen receptor positive breast cancer4–6. The gene discussed is ESR1; the disease is breast carcinoma.